Cargando…

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775

The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21 (HCT116 p21(-/-), RPE p21(-/-), and U2OS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hauge, Sissel, Macurek, Libor, Syljuåsen, Randi G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527284/ https://www.ncbi.nlm.nih.gov/pubmed/30943845 http://dx.doi.org/10.1080/15384101.2019.1593649

Ejemplares similares

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading
por: Hauge, Sissel, et al.
Publicado: (2016)

Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
por: Rødland, Gro Elise, et al.
Publicado: (2021)

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
por: Kreahling, Jenny M., et al.
Publicado: (2013)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2018)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2017)

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
por: Qi, Wenxiu, et al.
Publicado: (2014)

Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases
por: Eek Mariampillai, Adrian, et al.
Publicado: (2023)

Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis
por: Chen, Dongshao, et al.
Publicado: (2018)

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
por: Sørensen, Claus Storgaard, et al.
Publicado: (2012)

Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP–E2F1–DNA damage response pathway axis
por: Oku, Yusuke, et al.
Publicado: (2018)

Targeting lung cancer through inhibition of checkpoint kinases
por: Syljuåsen, Randi G., et al.
Publicado: (2015)

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo
por: Bi, Shuning, et al.
Publicado: (2019)

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
por: Serpico, Angela Flavia, et al.
Publicado: (2019)

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
por: Bauer, Todd M., et al.
Publicado: (2023)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
por: Zhou, Liang, et al.
Publicado: (2014)

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022)

Caspase activation counteracts interferon signaling after G2 checkpoint abrogation by ATR inhibition in irradiated human cancer cells
por: Eek Mariampillai, Adrian, et al.
Publicado: (2022)

WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)

Polo-like kinase 1 inhibits DNA damage response during mitosis
por: Benada, Jan, et al.
Publicado: (2015)

Residual Cdk1/2 activity after DNA damage promotes senescence
por: Müllers, Erik, et al.
Publicado: (2017)

Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1
por: Bukhari, Amirali B., et al.
Publicado: (2022)

Mathias Mayor (1775–1847)
por: Librach, I. M.
Publicado: (1970)

Medicine in Charlestown in 1750-1775
por: Waring, Joseph Ioor
Publicado: (1935)

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
por: Seligmann, Jenny F., et al.
Publicado: (2021)

Fundación Piadosa en Veracurz 1775
por: Gil, Francisco
Publicado: (1964)

Health Education From 1775 to 2005
por: Wilcox, Lynne S.
Publicado: (2005)

The Army Medical Department 1775–1818
por: Watt, Sir James
Publicado: (1982)

The Doctor in French Drama, 1700-1775
por: Smith, Geo. H.
Publicado: (1938)

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
por: Lin, Xiaoting, et al.
Publicado: (2018)

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma
por: Lindenblatt, Dennis, et al.
Publicado: (2018)

Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma
por: Anichini, Giulia, et al.
Publicado: (2023)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
por: Ha, Dong-Hyeon, et al.
Publicado: (2020)

Phosphorylation of TRF2 promotes its interaction with TIN2 and regulates DNA damage response at telomeres
por: Storchova, Radka, et al.
Publicado: (2023)

DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase
por: Brazina, Jan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ma9hdpinauiqjiecg70q84n21q